SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Enanta Pharmaceuticals Doses First Patient in Zelicapavir Phase 2b/3 Study

The global study will evaluate symptom duration and hospitalization rates in adult outpatients with respiratory syncytial virus.

ENTA

Related stories